Fatty liver may alter statin effects in kids, study warns
NCT ID NCT04903223
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how liver fat changes the way the body processes rosuvastatin, a common cholesterol drug, in children aged 8 to 21. Researchers will give a single dose to 50 kids with high cholesterol and measure drug levels and response. The goal is to understand if fatty liver increases the risk of side effects or makes the drug less effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rosuvastatin 10mg
- What this could lead to
- If successful, this could help doctors personalize statin doses for children with fatty liver, reducing risk of side effects or treatment failure.
- What could go wrong
- This is a small, early-phase study (50 participants) focused on understanding drug behavior, not testing a new treatment. Results may not apply to all children.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLESTEROL; LIPIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Mercy Hospital
RECRUITINGKansas City, Missouri, 64108, United States